1
|
Clustering Trend Changes of Lung Cancer Incidence in Europe via the Growth Mixture Model during 1990-2016. JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH 2021; 2021:8854446. [PMID: 33897783 PMCID: PMC8052171 DOI: 10.1155/2021/8854446] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 03/21/2021] [Accepted: 03/30/2021] [Indexed: 11/17/2022]
Abstract
Background Lung cancer accounts for half of all deaths from cancer in Europe and has the highest incidence in Southern Europe. The current study aimed to cluster trend changes of lung cancer incidence in Europe via the growth mixture model. Methods The dataset included incidence rates of female and male lung cancer per 100,000 for 42 European countries during 1990–2016 compiled from the Gapminder database. The growth mixture model was implemented to recognize different longitudinal patterns and estimate the linear trend of each pattern in Mplus 7.4 software. Results The observed overall trend of incidence for female and male lung cancer was raising and falling, respectively, and Iceland was the only country with higher incidence of female versus male lung cancer in 2016. The growth mixture model suggests 3 main patterns for the trend of lung cancer incidence both for males and females. In male lung cancer, a sharp decreasing pattern was detected for 6 countries including Belarus, Estonia, Russia, Slovenia, Ukraine, and the United Kingdom; also, a moderately decreasing pattern was observed among the other countries. In female lung cancer, a moderate increasing trend was observed for 8 countries including the United Kingdom, Denmark, Hungary, Iceland, Ireland, Montenegro, Netherlands, and Norway; the other patterns were categorized into two clusters with slow increasing trends. Conclusion Given the raising patterns in the incidence of lung cancer among European females, especially in the United Kingdom, Denmark, Hungary, Iceland, Ireland, Montenegro, Netherlands, and Norway, urgent effective measures are recommended to be taken.
Collapse
|
2
|
Martín-Sánchez JC, González-Marrón A, Lidón-Moyano C, Matilla-Santander N, Fu M, Vidal C, Garcia M, Martinez-Sanchez JM. Smoking pattern and risk of lung cancer among women participating in cancer screening programmes. J Public Health (Oxf) 2020; 42:90-97. [PMID: 30608591 DOI: 10.1093/pubmed/fdy221] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 10/25/2018] [Indexed: 12/28/2022] Open
Abstract
OBJECTIVES The aim of this study was to describe the smoking prevalence, the smoking pattern, and the risk of lung cancer among women who participated in a cancer screening (breast, cervical and colorectal) in Spain. METHODS We used data from the Spanish National Health Survey of 2011-12, a cross-sectional study of the adult Spanish population from women in the age of participation in the population cancer screening. We used two definitions of the high risk of lung cancer according to the National Lung Screening Trial (NLST) criteria and the NELSON criteria. RESULTS Participation in screening was 76.6% in breast cancer, 6.6% in colorectal cancer, and 70.3% in cervical cancer. The percentage of current smokers was 17.1 of women who participated breast cancer, 15.4 of women who participated colorectal cancer, and 26.1 of women who participated cervical cancer. According to NLST criteria, the percentage of current smokers women who had a high risk of lung cancer was 23.1 for breast cancer, 23.5 for colorectal cancer and 4.5 for cervical cancer. These figures were higher with the NELSON criteria. CONCLUSION At least 250 000 women in Spain have a high risk of lung cancer and are participating in a cancer screening programme. These programmes might be an opportunity for implementing specific interventions aiming to reduce this risk.
Collapse
Affiliation(s)
- Juan C Martín-Sánchez
- Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain
| | - Adrián González-Marrón
- Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain
| | - Cristina Lidón-Moyano
- Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain
| | - Nuria Matilla-Santander
- Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain
| | - Marcela Fu
- Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain.,Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, 08908 L'Hospitalet de Llobregat, Spain
| | - Carmen Vidal
- Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, 08908 L'Hospitalet de Llobregat, Spain.,Cancer Screening Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain
| | - Montse Garcia
- Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, 08908 L'Hospitalet de Llobregat, Spain.,Cancer Screening Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain
| | - Jose M Martinez-Sanchez
- Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, 08195 Sant Cugat del Vallès, Spain.,Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology (ICO), 08908 L'Hospitalet de Llobregat, Spain.,Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, 08908 L'Hospitalet de Llobregat, Spain
| |
Collapse
|
3
|
Martín-Sánchez JC, Bilal U, Clèries R, Lidón-Moyano C, Fu M, González-de Paz L, Franco M, Fernandez E, Martínez-Sánchez JM. Modelling lung cancer mortality rates from smoking prevalence: Fill in the gap. Cancer Epidemiol 2017; 49:19-23. [PMID: 28528290 DOI: 10.1016/j.canep.2017.04.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 03/10/2017] [Accepted: 04/25/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND The objective of this study is to estimate the gap between smoking prevalence and lung cancer mortality and provide predictions of lung cancer mortality based on previous smoking prevalence. MATERIALS AND METHODS We used data from the Spanish National Health Surveys (2003, 2006 and 2011) to obtain information about tobacco use and data from the Spanish National Statistics Institute to obtain cancer mortality rates from 1980 to 2013. We calculated the cross-correlation among the historical series of smoking prevalence and lung cancer mortality rate (LCMR) to estimate the most likely time gap between both series. We also predicted the magnitude and timing of the LCMR peak. RESULTS All cross-correlations were statistically significant and positive (all above 0.8). For men, the most likely gap ranges from 20 to 34 years. The age-adjusted LCMR increased by 3.2 deaths per 100,000 people for every 1 unit increase in the smoking prevalence 29 years earlier. The highest rate for men was observed in 1995 (55.6 deaths). For women, the most likely gap ranges from 10 to 37 years. The age-adjusted LCMR increased by 0.28 deaths per 100,000 people for every 1 unit increase in the smoking prevalence 32 years earlier. The maximum rate is expected to occur in 2026 (10.3 deaths). CONCLUSION The time series of prevalence of tobacco smoking explains the mortality from lung cancer with a distance (or gap) of around 30 years. According to the lagged smoking prevalence, the lung cancer mortality among men is declining while in women continues to rise (maximum expected in 2026).
Collapse
Affiliation(s)
- Juan Carlos Martín-Sánchez
- Group of Evaluation of Health Determinants and Health Policies, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain
| | - Usama Bilal
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Surgery, Medical and Social Sciences, Universidad de Alcalá, Madrid, Spain
| | - Ramon Clèries
- Plan for Oncology of the Catalan Government, L'Hospitalet de Llobregat, Spain; Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain
| | - Cristina Lidón-Moyano
- Group of Evaluation of Health Determinants and Health Policies, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain
| | - Marcela Fu
- Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain; Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Spain; Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Spain
| | - Luís González-de Paz
- Centre Atenció Primària Les Corts, Transverse Group for Research in Primary Care, IDIBAPS, Barcelona, Spain
| | - Manuel Franco
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Surgery, Medical and Social Sciences, Universidad de Alcalá, Madrid, Spain
| | - Esteve Fernandez
- Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain; Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Spain; Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Spain
| | - Jose M Martínez-Sánchez
- Group of Evaluation of Health Determinants and Health Policies, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain; Tobacco Control Unit, Cancer Prevention and Control Programme, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Spain; Cancer Control and Prevention Group, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Spain.
| |
Collapse
|
4
|
Garrido P, Sánchez M, Belda Sanchis J, Moreno Mata N, Artal Á, Gayete Á, Matilla González JM, Galbis Caravajal JM, Isla D, Paz-Ares L, Seijo LM. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. Arch Bronconeumol 2017; 53:568-573. [PMID: 28416207 DOI: 10.1016/j.arbres.2017.03.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 03/07/2017] [Accepted: 03/08/2017] [Indexed: 12/17/2022]
Abstract
Lung cancer (LC) is a major public health issue. Despite recent advances in treatment, primary prevention and early diagnosis are key to reducing the incidence and mortality of this disease. A recent clinical trial demonstrated the efficacy of selective screening by low-dose computed tomography (LDCT) in reducing the risk of both lung cancer mortality and all-cause mortality in high-risk individuals. This article contains the reflections of an expert group on the use of LDCT for early diagnosis of LC in high-risk individuals, and how to evaluate its implementation in Spain. The expert group was set up by the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), the Spanish Society of Thoracic Surgery (SECT), the Spanish Society of Radiology (SERAM) and the Spanish Society of Medical Oncology (SEOM).
Collapse
Affiliation(s)
- Pilar Garrido
- Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, España.
| | - Marcelo Sánchez
- Servicio de Radiodiagnóstico, Hospital Clínic, Barcelona, España
| | - José Belda Sanchis
- Servicio Mancomunado de Cirugía Torácica, Hospitales Universitari Mútua Terrassa, Sant Pau i Santa Creu y Mar, Barcelona, España
| | - Nicolás Moreno Mata
- Servicio de Cirugía Torácica, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - Ángel Artal
- Servicio de Oncología Médica, Hospital Universitario Miguel Servet, Zaragoza, España
| | - Ángel Gayete
- Servicio de Radiodiagnóstico, Hospital del Mar, Barcelona, España
| | | | | | - Dolores Isla
- Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
| | - Luis Paz-Ares
- Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, España
| | - Luis M Seijo
- Servicio de Neumología, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria, CIBERES, Madrid, España
| |
Collapse
|
5
|
Bayesian prediction of lung and breast cancer mortality among women in Spain (2014-2020). Cancer Epidemiol 2016; 43:22-9. [PMID: 27318304 DOI: 10.1016/j.canep.2016.05.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Revised: 04/11/2016] [Accepted: 05/30/2016] [Indexed: 11/21/2022]
Abstract
BACKGROUND Breast cancer (BC) is the main cause of cancer mortality among women, and mortality from lung cancer (LC) is increasing among women. The purpose of the present study was to project the mortality rates of both cancers and predict when LC mortality will exceed BC mortality. METHODS The cancer mortality data and female population distribution were obtained from the Spanish National Statistics Institute. Crude rate (CR), age-standardized rate (ASR), and age-specific rate were calculated for the period 1980-2013 and projected for the period 2014-2020 using a Bayesian log-linear Poisson model. RESULTS All calculated rates were greater for BC than for LC in 2013 (CR, 27.3 versus 17.3; ASR, 13.5 versus 9.3), and the CR was not projected to change by 2020 (29.2 versus 27.6). The ASR for LC is expected to surpass that of BC in 2019 (12.9 versus 12.7). CONCLUSIONS By 2020 the LC mortality rates may exceed those of BC for ages 55-74 years, possibly because of the prevalence of smoking among women, and the screening for and more effective treatment of BC. BC screening could be a good opportunity to help smokers quit by offering counseling and behavioral intervention.
Collapse
|